Literature DB >> 9669786

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

J Q Purnell1, J E Hokanson, S M Marcovina, M W Steffes, P A Cleary, J D Brunzell.   

Abstract

CONTEXT: Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment.
OBJECTIVE: To determine the effect of this weight gain on lipid levels and blood pressure.
DESIGN: Randomized controlled trial; ancillary study of the Diabetes Control and Complications Trial (DCCT).
SETTING: Twenty-one clinical centers. PARTICIPANTS: The 1168 subjects enrolled in DCCT with type 1 diabetes who were aged 18 years or older at baseline. INTERVENTION: Randomized to receive either intensive (n = 586) or conventional (n = 582) diabetes treatment with a mean follow-up of 6.1 years. MAIN OUTCOME MEASURES: Plasma lipid levels and blood pressure in each treatment group categorized by quartile of weight gain.
RESULTS: With intensive treatment, subjects in the fourth quartile of weight gain had the highest body mass index (BMI) (a measure of weight adjusted for height), blood pressure, and levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B compared with the other weight gain quartiles with the greatest difference seen when compared with the first quartile (mean values for the highest and lowest quartiles: BMI, 31 vs 24 kg/m2; blood pressure, 120/77 mm Hg vs 113/73 mm Hg; triglyceride, 0.99 mmol/L vs 0.79 mmol/L [88 mg/dL vs 70 mg/dL]; LDL-C, 3.15 mmol/L vs 2.74 mmol/L [122 mg/dL vs 106 mg/dL]; and apolipoprotein B, 0.89 g/L vs 0.78 g/L; all P<.001). In addition, the fourth quartile group had a higher waist-to-hip ratio; more cholesterol in the very low density lipoprotein, intermediate dense lipoprotein, and dense LDL fractions; and lower high-density lipoprotein cholesterol and apolipoprotein A-I levels compared with the first quartile. Baseline characteristics were not different between the first and fourth quartiles of weight gain with intensive therapy except for a higher hemoglobin A1c in the fourth quartile. Weight gain with conventional therapy resulted in smaller increases in BMI, lipids, and systolic blood pressure.
CONCLUSIONS: The changes in lipid levels and blood pressure that occur with excessive weight gain with intensive therapy are similar to those seen in the insulin resistance syndrome and may increase the risk of coronary artery disease in this subset of subjects with time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669786      PMCID: PMC2622729          DOI: 10.1001/jama.280.2.140

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   157.335


  21 in total

1.  The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men.

Authors:  A Tchernof; B Lamarche; D Prud'Homme; A Nadeau; S Moorjani; F Labrie; P J Lupien; J P Després
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

2.  Adverse events and their association with treatment regimens in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes Care       Date:  1995-11       Impact factor: 19.112

3.  Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance.

Authors:  C Hollenbeck; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  1987-06       Impact factor: 5.958

4.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

Authors:  C D Gardner; S P Fortmann; R M Krauss
Journal:  JAMA       Date:  1996-09-18       Impact factor: 56.272

5.  A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.

Authors:  M J Stampfer; R M Krauss; J Ma; P J Blanche; L G Holl; F M Sacks; C H Hennekens
Journal:  JAMA       Date:  1996-09-18       Impact factor: 56.272

6.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

7.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

8.  The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results.

Authors:  J S Dorman; R E Laporte; L H Kuller; K J Cruickshanks; T J Orchard; D K Wagener; D J Becker; D E Cavender; A L Drash
Journal:  Diabetes       Date:  1984-03       Impact factor: 9.461

9.  Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus.

Authors:  A S Krolewski; E J Kosinski; J H Warram; O S Leland; E J Busick; A C Asmal; L I Rand; A R Christlieb; R F Bradley; C R Kahn
Journal:  Am J Cardiol       Date:  1987-04-01       Impact factor: 2.778

10.  Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group.

Authors:  V A Koivisto; L K Stevens; M Mattock; P Ebeling; M Muggeo; J Stephenson; B Idzior-Walus
Journal:  Diabetes Care       Date:  1996-07       Impact factor: 19.112

View more
  124 in total

1.  Temporal patterns in overweight and obesity in Type 1 diabetes.

Authors:  B Conway; R G Miller; T Costacou; L Fried; S Kelsey; R W Evans; T J Orchard
Journal:  Diabet Med       Date:  2010-04       Impact factor: 4.359

Review 2.  Cardiovascular disease risk in young people with type 1 diabetes.

Authors:  Janet K Snell-Bergeon; Kristen Nadeau
Journal:  J Cardiovasc Transl Res       Date:  2012-04-12       Impact factor: 4.132

3.  Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study.

Authors:  C Kim; R S Miller; B H Braffett; Y Pan; V L Arends; A K Saenger; A Barnie; A V Sarma
Journal:  Clin Endocrinol (Oxf)       Date:  2018-01-26       Impact factor: 3.478

4.  Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.

Authors:  Melanie Cree-Green; Bryan C Bergman; Eda Cengiz; Larry A Fox; Tamara S Hannon; Kellee Miller; Brandon Nathan; Laura Pyle; Darcy Kahn; Michael Tansey; Eileen Tichy; Eva Tsalikian; Ingrid Libman; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

5.  Velocity-weighting & velocity-penalty MPC of an artificial pancreas: Improved safety & performance.

Authors:  Ravi Gondhalekar; Eyal Dassau; Francis J Doyle
Journal:  Automatica (Oxf)       Date:  2018-03-20       Impact factor: 5.944

6.  Relationship between lipid profiles and kidney function in patients with type 1 diabetes.

Authors:  N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; O Heikkilä; K Pettersson-Fernholm; M-R Taskinen; P-H Groop
Journal:  Diabetologia       Date:  2007-11-10       Impact factor: 10.122

7.  Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.

Authors:  Jonathan Q Purnell; Raj K Dev; Michael W Steffes; Patricia A Cleary; Jerry P Palmer; Irl B Hirsch; John E Hokanson; John D Brunzell
Journal:  Diabetes       Date:  2003-10       Impact factor: 9.461

8.  Glycemic control and variability in association with body mass index and body composition over 18months in youth with type 1 diabetes.

Authors:  Leah M Lipsky; Benjamin Gee; Aiyi Liu; Tonja R Nansel
Journal:  Diabetes Res Clin Pract       Date:  2016-08-06       Impact factor: 5.602

9.  Secular trends in growth in diabetes: are we winning?

Authors:  K C Donaghue; O Kordonouri; A Chan; M Silink
Journal:  Arch Dis Child       Date:  2003-02       Impact factor: 3.791

10.  Do European people with type 1 diabetes consume a high atherogenic diet? 7-year follow-up of the EURODIAB Prospective Complications Study.

Authors:  Sabita S Soedamah-Muthu; Nish Chaturvedi; John H Fuller; Monika Toeller
Journal:  Eur J Nutr       Date:  2012-12-07       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.